-- Robert Preidt
FRIDAY, Sept. 27 (HealthDay News) -- An older and little-used
class of antidepressants may help combat a particularly deadly form
of lung cancer, according to a new study.
Using a unique computer program, researchers from the Stanford
University School of Medicine identified tricyclic antidepressants
as a potential treatment for small cell lung cancer. This class of
drugs was introduced decades ago and is still approved for use in
the United States, but has been supplanted by newer antidepressants
with fewer side effects.
Follow-up experiments showed that the tricyclic antidepressant
called imipramine (Tofranil), was effective against human small
cell lung cancer cells grown in the laboratory and growing as
tumors in mice. The drug activated a self-destruction pathway in
the cancer cells and slowed or blocked the spread of cancer in
Imipramine maintained its effectiveness regardless of whether
the cancer cells had previously been exposed, and become resistant,
to traditional chemotherapy treatments, according to the study,
which was published online Sept. 27 in the journal
Because tricyclic antidepressants already have U.S. Food and
Drug Administration approval for use in people, the Stanford team
was quickly able to launch a clinical trial to test imipramine in
patients with small cell lung cancer and certain other types of
cancer. They are currently recruiting patients for the phase-2
"We are cutting down the decade or more and the $1 billion it can typically take to translate a laboratory finding into a successful drug treatment to about one to two years and spending about $100,000," study co-senior author Dr. Atul Butte, director of the Center for Pediatric Bioinformatics at Lucile Packard Children's Hospital at Stanford, said in a university news release.
"The five-year survival for small cell lung cancer is only 5 percent," study co-senior author Julien Sage, an associate professor of pediatrics, said in the news release. "There has not been a single efficient therapy developed in the last 30 years. But when we began to test these drugs in human cancer cells grown in a dish and in a mouse model, they worked, and they worked, and they worked."
Another drug, an antihistamine called promethazine (Phenergan),
also exhibited the ability to kill cancer cells, according to the
The U.S. National Cancer Institute has more about
small cell lung cancer.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.